Abstract
Introduction: The risk of cancer with the use of biologic agents in rheumatic diseases is still a matter of debate. Published data suggest that the extent of cancer risk might differ according to the type of cancer, and there is recent clinical evidence for a significant increased risk for skin cancer, including melanoma. In contrast with the extensive literature on cancer risk in rheumatoid arthritis, little has been reported on the development of malignancies in spondyloarthroparthies.
Case Presentation: We report the case of an otherwise healthy 31-year-old Italian woman with psoriasic arthritis who developed a melanoma of left third toe with metastatic involvement of regional lymphnodes after a 3-year treatment with the TNF-alpha inhibitor adalimumab.
Conclusion: This case illustrates the possibility of a causal relationship between TNF-alpha inhibitors and melanoma. We believe that vigilance should continue in patients treated with TNF-alpha blocking agents, until the question on the increased incidence of cancers, including skin cancers, associated with these drugs will be defined.
Keywords: Psoriatic arthritis, melanoma, adalimumab, rheumatic disease, spondyloarthroparthies, reginoal lymphnodes, TNF-alpha inhibiotrs, skin cancer
Current Drug Safety
Title: Metastatic Melanoma in a Young Woman Treated with TNF-Alpha Inhibitor for Psoriatic Arthritis: A Case Report
Volume: 6 Issue: 4
Author(s): Bianca Marasini, Luca Cozzaglio, Laura Belloli, Marco Massarotti, Nicola Ughi and Paolo Pedrazzoli
Affiliation:
Keywords: Psoriatic arthritis, melanoma, adalimumab, rheumatic disease, spondyloarthroparthies, reginoal lymphnodes, TNF-alpha inhibiotrs, skin cancer
Abstract: Introduction: The risk of cancer with the use of biologic agents in rheumatic diseases is still a matter of debate. Published data suggest that the extent of cancer risk might differ according to the type of cancer, and there is recent clinical evidence for a significant increased risk for skin cancer, including melanoma. In contrast with the extensive literature on cancer risk in rheumatoid arthritis, little has been reported on the development of malignancies in spondyloarthroparthies.
Case Presentation: We report the case of an otherwise healthy 31-year-old Italian woman with psoriasic arthritis who developed a melanoma of left third toe with metastatic involvement of regional lymphnodes after a 3-year treatment with the TNF-alpha inhibitor adalimumab.
Conclusion: This case illustrates the possibility of a causal relationship between TNF-alpha inhibitors and melanoma. We believe that vigilance should continue in patients treated with TNF-alpha blocking agents, until the question on the increased incidence of cancers, including skin cancers, associated with these drugs will be defined.
Export Options
About this article
Cite this article as:
Marasini Bianca, Cozzaglio Luca, Belloli Laura, Massarotti Marco, Ughi Nicola and Pedrazzoli Paolo, Metastatic Melanoma in a Young Woman Treated with TNF-Alpha Inhibitor for Psoriatic Arthritis: A Case Report, Current Drug Safety 2011; 6 (4) . https://dx.doi.org/10.2174/157488611798280915
DOI https://dx.doi.org/10.2174/157488611798280915 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Androgen Receptor Mutations in Prostate Cancer Progression
Current Genomics Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery Computer-aided Diagnosis of Skin Cancer: A Review
Current Medical Imaging Computational Analysis of Drug Resistance Network in Lung Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology Biosafety Considerations Using Gamma-Retroviral Vectors in Gene Therapy
Current Gene Therapy A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
Mini-Reviews in Medicinal Chemistry Juglone Exerts Cytotoxic, Anti-proliferative and Anti-invasive Effects on Glioblastoma Multiforme in a Cell Culture Model
Anti-Cancer Agents in Medicinal Chemistry A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Effect of Botanicals on Inflammation and Skin Aging: Analyzing the Evidence
Inflammation & Allergy - Drug Targets (Discontinued) Proteome Analysis of Formalin-Fixed Paraffin-Embedded Tissues from a Primary Gastric Melanoma and its Meningeal Metastasis: A Case Report
Current Topics in Medicinal Chemistry Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Peptide-Oligonucleotide Hybrids in Antisense Therapy
Mini-Reviews in Medicinal Chemistry Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry The Role of the Chaperone Grp94/Gp96 in the Intestinal Barrier and Innate Immune Functions
Current Immunology Reviews (Discontinued) An Overview of Interleukin-1 Receptor Antagonist, Anakinra, in the Treatment of Cutaneous Diseases
Current Clinical Pharmacology Recent Advances in Coumarins and 1-Azacoumarins as Versatile Biodynamic Agents
Current Medicinal Chemistry Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Current Neuropharmacology